Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Tauopathies 2Neurodegenerative Diseases 2Nervous System Diseases 2Mental Disorders 2Inflammation 2Dementia 2Central Nervous System Diseases 2Brain Diseases 2Alzheimer Disease 2Neurocognitive Disorders 1Cognitive Dysfunction 1

Interventions

XENP 1595 2Electroencephalography 2mazdutide 1enzalutamide 1amlodipine, atorvastatin drug combination 1UE2343 1Tomography, X-Ray Computed 1Tomography, Emission-Computed 1Tablets 1Standard of Care 1Referral and Consultation 1Prednisone 1Positron-Emission Tomography 1Methotrexate 1Methods 1Magnetic Resonance Imaging 1Lysine Acetyltransferase 5 1Hormones 1Gonadotropin-Releasing Hormone 1Exercise 1Ethanol 1Drug Delivery Systems 1Dignity Therapy 1Decision Support Techniques 1Atorvastatin 1Aging 1Activities of Daily Living 1Accidental Falls 1Abiraterone Acetate 17-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Dementia × XENP 1595 × Clear all
NCT05522387 2026-02-27

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Inmune Bio, Inc.

Phase 2 Terminated
11 enrolled
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Tauopathies

NCT05321498 2023-09-28

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Inmune Bio, Inc.

Phase 2 Withdrawn
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Tauopathies, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡